ATE475429T1 - Behandlung der spastischen blase mit botulinustoxin - Google Patents

Behandlung der spastischen blase mit botulinustoxin

Info

Publication number
ATE475429T1
ATE475429T1 AT04798493T AT04798493T ATE475429T1 AT E475429 T1 ATE475429 T1 AT E475429T1 AT 04798493 T AT04798493 T AT 04798493T AT 04798493 T AT04798493 T AT 04798493T AT E475429 T1 ATE475429 T1 AT E475429T1
Authority
AT
Austria
Prior art keywords
bladder
unstable
sphincter
detrusor
treatment
Prior art date
Application number
AT04798493T
Other languages
English (en)
Inventor
Chris Dott
John Batchelor
D Arbigny Pierre Bernard
Roland Cherif-Cheikh
Original Assignee
Ipsen Pharma
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29764527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE475429(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Pharma, Ipsen Biopharm Ltd filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE475429T1 publication Critical patent/ATE475429T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT04798493T 2003-12-04 2004-11-12 Behandlung der spastischen blase mit botulinustoxin ATE475429T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328060.9A GB0328060D0 (en) 2003-12-04 2003-12-04 Botulinum toxin treatment
PCT/GB2004/004770 WO2005053733A1 (en) 2003-12-04 2004-11-12 Botulinum toxin treatment of spastic bladder

Publications (1)

Publication Number Publication Date
ATE475429T1 true ATE475429T1 (de) 2010-08-15

Family

ID=29764527

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798493T ATE475429T1 (de) 2003-12-04 2004-11-12 Behandlung der spastischen blase mit botulinustoxin

Country Status (13)

Country Link
US (2) US20070275110A1 (de)
EP (1) EP1691828B1 (de)
JP (1) JP5107578B2 (de)
AT (1) ATE475429T1 (de)
CA (1) CA2547618C (de)
DE (1) DE602004028403D1 (de)
DK (1) DK1691828T3 (de)
ES (1) ES2347151T3 (de)
GB (1) GB0328060D0 (de)
PL (1) PL1691828T3 (de)
PT (1) PT1691828E (de)
RU (1) RU2350348C2 (de)
WO (1) WO2005053733A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
CN1930186A (zh) 2005-03-03 2007-03-14 阿勒根公司 为获得梭菌毒素的梭菌细菌培养基及方法
WO2008030638A2 (en) * 2006-05-16 2008-03-13 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
CA2678038C (en) 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
RU2010120016A (ru) 2007-10-23 2011-11-27 Аллерган, Инк. (Us) Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
EP2836200B1 (de) * 2012-04-08 2020-07-15 Urogen Pharma Ltd. Thermoreversible hydrogelpräparate zur behandlung von erkrankungen des urothels
CN107072971A (zh) * 2014-09-24 2017-08-18 韦尔斯利医药有限公司 用于减轻膀胱痉挛的药学制剂及其使用方法
RU2605624C1 (ru) * 2015-11-23 2016-12-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Способ лечения детрузорной гиперактивности
HUE046449T2 (hu) 2016-09-13 2020-03-30 Allergan Inc Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
KR20230118632A (ko) 2020-12-11 2023-08-11 우로젠 파마 엘티디. 암을 치료하기 위한 물질 및 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8804003D0 (sv) * 1988-11-04 1988-11-04 Pharmacia Ab Compounds for the treatment of urinary incontinence
US5236956A (en) 1988-11-04 1993-08-17 Kabi Pharmacia Aktiebolag Compounds for the treatment of urinary incontinence
JPH0564661A (ja) * 1991-09-09 1993-03-19 Olympus Optical Co Ltd 体腔内挿入具
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5749845A (en) 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
CA2505933C (en) * 1997-07-15 2008-09-30 Richard A. Schmidt Use of botulinum toxin for treating urinary incontinence
US6630570B1 (en) 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
US6579847B1 (en) * 2000-05-01 2003-06-17 Imarx Therapeutics Inc. Method and apparatus for vascular neuromuscular blockade
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6638246B1 (en) * 2000-11-28 2003-10-28 Scimed Life Systems, Inc. Medical device for delivery of a biologically active material to a lumen
US20020099356A1 (en) * 2001-01-19 2002-07-25 Unger Evan C. Transmembrane transport apparatus and method
US7226605B2 (en) * 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
MXPA04006875A (es) * 2002-01-18 2004-12-06 Control Delivery Sys Inc Sistema de gel polimerico para suministro controlado de cofarmacos.
AU2003259246A1 (en) * 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders

Also Published As

Publication number Publication date
US8277822B2 (en) 2012-10-02
JP5107578B2 (ja) 2012-12-26
JP2007513127A (ja) 2007-05-24
CA2547618A1 (en) 2005-06-16
WO2005053733A1 (en) 2005-06-16
RU2006123561A (ru) 2008-01-10
EP1691828B1 (de) 2010-07-28
DK1691828T3 (da) 2010-11-01
DE602004028403D1 (de) 2010-09-09
US20070275110A1 (en) 2007-11-29
EP1691828A1 (de) 2006-08-23
PL1691828T3 (pl) 2011-01-31
CA2547618C (en) 2014-05-27
US20090028907A1 (en) 2009-01-29
RU2350348C2 (ru) 2009-03-27
PT1691828E (pt) 2010-10-04
GB0328060D0 (en) 2004-01-07
ES2347151T3 (es) 2010-10-26

Similar Documents

Publication Publication Date Title
ATE475429T1 (de) Behandlung der spastischen blase mit botulinustoxin
Smith et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra
DE69835911D1 (de) Verwendung einer Neurotoxintherapie zur Behandlung der Harnverhaltung
Raz et al. External sphincter spasticity syndrome in female patients
JP2007513127A5 (de)
Vera et al. MK-801, a non-competitive NMDA receptor antagonist, produces facilitation of the micturition reflex in awake, freely-moving rats
AU2002348370B2 (en) Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
Pedersen et al. Effect of the alpha‐adrenergic blocking agent thymoxamine on the neurogenic bladder and urethra
Schapiro The symptomatic management of multiple sclerosis
Rösche Treatment of spasticity
Jeong Fournier's gangrene associated with sparganosis in the scrotum
RU2018133365A (ru) Усовершенствованная схема инъекции в мочевой пузырь для введения ботулотоксинов
RU2721300C2 (ru) Способ лечения нейрогенной дисфункции мочевого пузыря, проявляющейся функциональной инфравезикальной обструкцией у женщин
Fowler et al. Bladder dysfunction in multiple sclerosis
Bae et al. The effects of α1A‐adrenoceptor antagonists on the urethral perfusion pressure of the female rat
US11766460B2 (en) Pharmaceutical composition comprising amniotic fluid stem cell spheroid and the use thereof in treatment of urinary incontinence
Thomley et al. Ureteral antispasmodic agents: experiences with atropine tannate
Tyagi A Review of Pharmacotherapy in the Treatment of Urinary Disorders
Dzigowski et al. Efficacy and safety of botulinum toxin non-neurogenic administration, a single center, single surgeon 7 years experience Article published in Urologia Polska 2008/61/Supl. 1.
Lyding LARGE DOSES OF BACTERIAL VACCINE IN GONORRHEAL ARTHRITIS
UA72418A (en) Method for treating hyperactivity of urinary bladder
Tiebin et al. Effectiveness of electrical stimulation of pelvic floor muscles in the treatment of urinary incontinence in patients with incomplete spinal cord injury
CHUANG et al. Bladder Botulinum Toxin
MacLennan et al. Bladder Disorders
Yuan et al. Acupuncture treatment of female urethral syndrome

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1691828

Country of ref document: EP